NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...

World Bank Deputy Chief Economist Ayhan Kose has said that the Japanese economy is expected to "deliver healthy growth" over the next two years driven by increased consumption backed by rising wages.

Moderna provides updates on its business and pipeline progress at the J.P. Morgan Healthcare Conference. Moderna reported preliminary product sales between $3 billion and $3.1 billion for 2024 ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Regeneron plans to submit trial data to the ... Adjuvant treatment with cemiplimab (Libtayo) significantly improves disease-free survival (DFS) in patients with high-risk cutaneous squamous ...